Related references
Note: Only part of the references are listed.Parkinson's disease peripheral immune biomarker profile: a multicentre, cross-sectional and longitudinal study
Yuanyuan Li et al.
JOURNAL OF NEUROINFLAMMATION (2022)
The Contribution of Microglia to Neuroinflammation in Parkinson's Disease
Katja Badanjak et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2021)
Parkinson's disease
Bastiaan R. Bloem et al.
LANCET (2021)
Antiseizure potential of peptides from the venom of social wasp Chartergellus communis against chemically-induced seizures
Kamila Soares Lopes et al.
TOXICON (2021)
Exenatide once weekly over 2 years as a potential disease-modifying treatment for Parkinson's disease: protocol for a multicentre, randomised, double blind, parallel group, placebo controlled, phase 3 trial: The 'Exenatide-PD3' study
Nirosen Vijiaratnam et al.
BMJ OPEN (2021)
Neuropolybin: A new antiseizure peptide obtained from wasp venom
Juliana de Castro e Silva et al.
BIOCHEMICAL PHARMACOLOGY (2020)
Fraternine, a Novel Wasp Peptide, Protects against Motor Impairments in 6-OHDA Model of Parkinsonism
Andreia Mayer Biolchi et al.
TOXINS (2020)
Neurodegeneration and Inflammation-An Interesting Interplay in Parkinson's Disease
Chrysoula Marogianni et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2020)
Neuropathology of Parkinson disease
Dennis W. Dickson
PARKINSONISM & RELATED DISORDERS (2018)
Therapeutic strategies for Parkinson disease: beyond dopaminergic drugs
Delphine Charvin et al.
NATURE REVIEWS DRUG DISCOVERY (2018)
Development of a novel RANKL-based peptide, microglial healing peptide1-AcN (MHP1-AcN), for treatment of ischemic stroke
Munehisa Shimamura et al.
SCIENTIFIC REPORTS (2018)
Exenatide once weekly versus placebo in Parkinson's disease: a randomised, double-blind, placebo-controlled trial
Dilan Athauda et al.
LANCET (2017)
Parkinson disease
Werner Poewe et al.
NATURE REVIEWS DISEASE PRIMERS (2017)
Bee venom for the treatment of Parkinson's disease: How far is it possible?
Kamal Awad et al.
BIOMEDICINE & PHARMACOTHERAPY (2017)
Cyclic Peptide Oral Bioavailability: Lessons From the Past
Conan K. Wang et al.
BIOPOLYMERS (2016)
The glucagon-like peptide 1 (GLP) receptor as a therapeutic target in Parkinson's disease: mechanisms of action
Dilan Athauda et al.
DRUG DISCOVERY TODAY (2016)
INTRANASAL INSULIN PROTECTS AGAINST SUBSTANTIA NIGRA DOPAMINERGIC NEURONAL LOSS AND ALLEVIATES MOTOR DEFICITS INDUCED BY 6-OHDA IN RATS
Y. Pang et al.
NEUROSCIENCE (2016)
Harnessing the knowledge of animal toxins to generate drugs
V. O. Zambelli et al.
PHARMACOLOGICAL RESEARCH (2016)
How neuroinflammation contributes to neurodegeneration
Richard M. Ransohoff
SCIENCE (2016)
Aberrations in Peripheral Inflammatory Cytokine Levels in Parkinson Disease A Systematic Review and Meta-analysis
Xiao-Yan Qin et al.
JAMA NEUROLOGY (2016)
Neuroactive compounds obtained from arthropod venoms as new therapeutic platforms for the treatment of neurological disorders
Victoria Monge-Fuentes et al.
JOURNAL OF VENOMOUS ANIMALS AND TOXINS INCLUDING TROPICAL DISEASES (2015)
The I-TASSER Suite: protein structure and function prediction
Jianyi Yang et al.
NATURE METHODS (2015)
Pathogenesis of Parkinson disease-the gut-brain axis and environmental factors
Lisa Klingelhoefer et al.
NATURE REVIEWS NEUROLOGY (2015)
Pharmacological Alternatives for the Treatment of Neurodegenerative Disorders: Wasp and Bee Venoms and Their Components as New Neuroactive Tools
Juliana Silva et al.
TOXINS (2015)
Glucagon-Like Peptide-1 Increases Mitochondrial Biogenesis and Function in INS-1 Rat Insulinoma Cells
Mi Yeon Kang et al.
ENDOCRINOLOGY AND METABOLISM (2015)
Motor and Cognitive Advantages Persist 12 Months After Exenatide Exposure in Parkinson's Disease
Iciar Aviles-Olmos et al.
JOURNAL OF PARKINSONS DISEASE (2014)
Insulin, incretins and other growth factors as potential novel treatments for Alzheimer's and Parkinson's diseases
Christian Hoelscher
BIOCHEMICAL SOCIETY TRANSACTIONS (2014)
MHCII Is Required for α-Synuclein-Induced Activation of Microglia, CD4 T Cell Proliferation, and Dopaminergic Neurodegeneratione
Ashley S. Harms et al.
JOURNAL OF NEUROSCIENCE (2013)
Review: Microglia in protein aggregation disorders: friend or foe?
S. M. Gentleman
NEUROPATHOLOGY AND APPLIED NEUROBIOLOGY (2013)
被撤回的出版物: Exendin-4 reverts behavioural and neurochemical dysfunction in a pre-motor rodent model of Parkinson's disease with noradrenergic deficit (Retracted article. See vol. 169, pg. 717, 2013)
N. Rampersaud et al.
BRITISH JOURNAL OF PHARMACOLOGY (2012)
Effectiveness of acupuncture and bee venom acupuncture in idiopathic Parkinson's disease
Seung-Yeon Cho et al.
PARKINSONISM & RELATED DISORDERS (2012)
Emerging roles of microglial activation and non-motor symptoms in Parkinson's disease
Karlijn J. Doorn et al.
PROGRESS IN NEUROBIOLOGY (2012)
Ab initio protein structure assembly using continuous structure fragments and optimized knowledge-based force field
Dong Xu et al.
PROTEINS-STRUCTURE FUNCTION AND BIOINFORMATICS (2012)
Presenting your structures: the CCP4mg molecular-graphics software
S. McNicholas et al.
ACTA CRYSTALLOGRAPHICA SECTION D-STRUCTURAL BIOLOGY (2011)
Bee Venom Reduces Neuroinflammation in the MPTP-Induced Model of Parkinson's Disease
Jong-In Kim et al.
INTERNATIONAL JOURNAL OF NEUROSCIENCE (2011)
Chemical and biological characterization of four new linear cationic α-helical peptides from the venoms of two solitary eumenine wasps
Marisa Rangel et al.
TOXICON (2011)
Exendin-4 protects pancreatic beta cells from human islet amyloid polypeptide-induced cell damage: potential involvement of AKT and mitochondria biogenesis
R. Fan et al.
DIABETES OBESITY & METABOLISM (2010)
Potassium Channel Modulation by a Toxin Domain in Matrix Metalloprotease 23
Srikant Rangaraju et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2010)
Kinin Receptor Antagonists as Potential Neuroprotective Agents in Central Nervous System Injury
Emma Thornton et al.
MOLECULES (2010)
Neuroprotective effects of bee venom pharmaceutical acupuncture in acute 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced mouse model of Parkinson's disease
Ah-Reum Doo et al.
NEUROLOGICAL RESEARCH (2010)
Peripheral cytokines profile in Parkinson's disease
M. Reale et al.
BRAIN BEHAVIOR AND IMMUNITY (2009)
Exendin-4 protects dopaminergic neurons by inhibition of microglial activation and matrix metalloproteinase-3 expression in an animal model of Parkinson's disease
Sehee Kim et al.
JOURNAL OF ENDOCRINOLOGY (2009)
Tentacles of Venom: Toxic Protein Convergence in the Kingdom Animalia
B. G. Fry et al.
JOURNAL OF MOLECULAR EVOLUTION (2009)
Neuropsychiatric Symptoms in Parkinson's Disease
Dag Aarsland et al.
MOVEMENT DISORDERS (2009)
Glucagon-like peptide I receptor stimulation reverses key deficits in distinct rodent models of Parkinson's disease
Alexander Harkavyi et al.
JOURNAL OF NEUROINFLAMMATION (2008)
Peptide hormone exendin-4 stimulates subventricular zone neurogenesis in the adult rodent brain and induces recovery in an animal model of Parkinson's disease
Goran Bertilsson et al.
JOURNAL OF NEUROSCIENCE RESEARCH (2008)
Inflammation as a causative factor in the aetiology of Parkinson's disease
P. S. Whitton
BRITISH JOURNAL OF PHARMACOLOGY (2007)
Genetic clues to the pathogenesis of Parkinson's disease
M Vila et al.
NATURE MEDICINE (2004)
Protection and reversal of excitotoxic neuronal damage by glucagon-like peptide-1 and exendin-4
T Perry et al.
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS (2002)
Share Paper
